Ladenburg analyst Jeffrey Cohen lowered the firm’s price target on Bionano Genomics to $5.20 from $6.80 and keeps a Buy rating on the shares after the company announced Q2 results and operational updates. Based on the company’s commentary, the firm is making adjustments to its models to align with the updated guidance, but with the CPT code, the launch of the higher throughput system, the comprehensive software updates, and the consistent publication of clinical data, the firm still sees the company having “a differentiated technology and the opportunity to grow awareness, adoption, and utilization globally,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics Reported Earnings. Did it Beat Estimates?
- Options Volatility and Implied Earnings Moves Today, August 07, 2024
- Options Volatility and Implied Earnings Moves This Week, August 05 – August 09, 2024
- Bionano Genomics announces participation at CGC 2024 meeting
- Bionano Genomics files to sell 35.035M share of common stock for holders